Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TGTX 
TG Therapeutics Inc (TGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $41.2
1 Year Target Price $41.2
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.53% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.83B USD | Price to earnings Ratio 149.96 | 1Y Target Price 41.2 |
Price to earnings Ratio 149.96 | 1Y Target Price 41.2 | ||
Volume (30-day avg) 7 | Beta 1.94 | 52 Weeks Range 16.65 - 46.48 | Updated Date 07/1/2025 |
52 Weeks Range 16.65 - 46.48 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.13% | Operating Margin (TTM) 7.13% |
Management Effectiveness
Return on Assets (TTM) 7.26% | Return on Equity (TTM) 19.7% |
Valuation
Trailing PE 149.96 | Forward PE 25.91 | Enterprise Value 5586139644 | Price to Sales(TTM) 15.09 |
Enterprise Value 5586139644 | Price to Sales(TTM) 15.09 | ||
Enterprise Value to Revenue 14.46 | Enterprise Value to EBITDA 79.25 | Shares Outstanding 158755008 | Shares Floating 135060602 |
Shares Outstanding 158755008 | Shares Floating 135060602 | ||
Percent Insiders 9.74 | Percent Institutions 63.24 |
Analyst Ratings
Rating 3 | Target Price 41.2 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell 1 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics, Inc. was founded in 2003. It is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. Initially focused on blood cancers, the company has evolved its pipeline through internal development and strategic acquisitions.
Core Business Areas
- Hematology/Oncology: Development and commercialization of therapies for hematologic malignancies (blood cancers).
- Autoimmune Diseases: Development of therapies for autoimmune diseases.
Leadership and Structure
Michael S. Weiss serves as the Chairman and Chief Executive Officer. The company has a typical organizational structure for a biotechnology company, with departments focused on research and development, clinical trials, regulatory affairs, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Ukoniq (umbralisib): A PI3K delta inhibitor approved for relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). Ukoniq was voluntarily withdrawn from the market in 2022. Competitors include other PI3K inhibitors such as Copiktra (duvelisib) from Secura Bio.
- Briumvi (ublituximab-xiiy): A CD20-directed cytolytic antibody approved for relapsing forms of multiple sclerosis (RMS). It is a competitor to Ocrevus (ocrelizumab) from Roche, Kesimpta (ofatumumab) from Novartis, and Mavenclad (cladribine) from EMD Serono.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. It is characterized by long development timelines, high regulatory hurdles, and significant investment in research and development. The areas of hematologic malignancies, autoimmune diseases, and multiple sclerosis are actively researched and feature established competitors.
Positioning
TG Therapeutics aims to develop differentiated therapies in areas with unmet medical needs. Briumvi is positioned as a potentially cost-effective option in the MS market. However, Ukoniq's market position was weakened by safety concerns that led to its withdrawal.
Total Addressable Market (TAM)
The total addressable market for multiple sclerosis therapies is significant, projected to be in the tens of billions of dollars annually. TG Therapeutics aims to capture a portion of this market with Briumvi. The TAM for B-cell lymphomas is also substantial, though TG Therapeutics' current focus in this area is limited after withdrawing Ukoniq.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Briumvi)
- Strong focus on B-cell malignancies and autoimmune diseases
- Experienced management team
- Differentiated product profile for Briumvi
Weaknesses
- Past Ukoniq issues and market withdrawal
- Reliance on a single key product (Briumvi)
- Competitive landscape with established players
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Further development of Briumvi for additional indications
- Partnerships and collaborations to expand pipeline
- Potential for acquisitions of complementary technologies
- Growth in the MS therapeutics market
Threats
- Competition from existing and emerging therapies
- Regulatory risks and challenges
- Patent expiration and generic entry
- Potential safety issues with Briumvi
- Market access and reimbursement challenges
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
- SNY
Competitive Landscape
TG Therapeutics faces intense competition in the MS market from established players with significant resources and established products. Briumvi needs to demonstrate superior value to gain market share. In lymphoma, competitors have more established positions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, influenced by clinical trial results and regulatory approvals. The withdrawal of Ukoniq significantly impacted previous growth projections.
Future Projections: Future growth is dependent on the commercial success of Briumvi and pipeline expansion. Analyst estimates can be found on various financial websites and brokerage reports.
Recent Initiatives: Focusing on Briumvi's commercialization and exploring potential indications are key recent initiatives.
Summary
TG Therapeutics' outlook hinges on Briumvi's success in the competitive MS market following the Ukoniq market withdrawal. While Briumvi offers a potential cost-effective option, it faces challenges from established competitors. The company needs to execute its commercial strategy effectively and manage financial resources carefully. Future growth depends on pipeline expansion and clinical trial successes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- TG Therapeutics' Investor Relations website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Market share data is approximate and based on available information, which may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 352 | Website https://www.tgtherapeutics.com |
Full time employees 352 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.